Agios Pharmaceuticals Inc (NASDAQ:AGIO) insider Scott Biller sold 3,000 shares of the business’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $65.00, for a total value of $195,000.00. Following the transaction, the insider now directly owns 56,059 shares of the company’s stock, valued at $3,643,835. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Scott Biller also recently made the following trade(s):
- On Friday, December 1st, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $60.79, for a total value of $130,455.34.
- On Wednesday, November 1st, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $62.69, for a total value of $134,532.74.
Shares of Agios Pharmaceuticals Inc (AGIO) traded up $2.57 during midday trading on Friday, reaching $75.11. The company’s stock had a trading volume of 671,099 shares, compared to its average volume of 419,764. Agios Pharmaceuticals Inc has a one year low of $39.24 and a one year high of $76.02. The stock has a market capitalization of $3,660.00, a PE ratio of -11.98 and a beta of 1.83.
Hedge funds and other institutional investors have recently modified their holdings of the business. QS Investors LLC purchased a new stake in Agios Pharmaceuticals in the second quarter valued at approximately $144,000. Cubist Systematic Strategies LLC lifted its stake in Agios Pharmaceuticals by 1,041.0% in the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 3,123 shares during the last quarter. Teacher Retirement System of Texas purchased a new stake in Agios Pharmaceuticals in the third quarter valued at approximately $225,000. S&CO Inc. purchased a new stake in Agios Pharmaceuticals in the third quarter valued at approximately $227,000. Finally, Macquarie Group Ltd. purchased a new stake in Agios Pharmaceuticals in the third quarter valued at approximately $245,000. Institutional investors own 93.79% of the company’s stock.
A number of brokerages recently issued reports on AGIO. SunTrust Banks reaffirmed a “buy” rating and issued a $80.00 price target on shares of Agios Pharmaceuticals in a report on Wednesday, October 4th. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $76.00 price target on shares of Agios Pharmaceuticals in a report on Monday, September 18th. Royal Bank of Canada began coverage on Agios Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $78.00 price target for the company. Credit Suisse Group upped their price target on Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a report on Thursday, November 2nd. Finally, Cann reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a report on Tuesday, December 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have given a buy rating to the stock. Agios Pharmaceuticals currently has an average rating of “Buy” and an average price target of $75.00.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/01/12/agios-pharmaceuticals-inc-agio-insider-sells-195000-00-in-stock.html.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.